Recent

% | $
Quotes you view appear here for quick access.

iRobot Corporation Message Board

opele1 152 posts  |  Last Activity: Feb 3, 2016 11:15 AM Member since: Nov 5, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Why postpone the earning release date?

    by andy.s927 Feb 2, 2016 7:07 PM
    opele1 opele1 Feb 3, 2016 11:15 AM Flag

    you and management both apparently

  • Reply to

    Why postpone the earning release date?

    by andy.s927 Feb 2, 2016 7:07 PM
    opele1 opele1 Feb 3, 2016 11:14 AM Flag

    negotiations on going trying to close before a big number costs more $$

  • the numbers more than likely blow out estimates the insiders know this realize after the results are out they get a better price? just food for thought...and congrats to all the longs I remember when this was 6$...nice to see a good one make it every now and again

  • opele1 opele1 Feb 3, 2016 9:25 AM Flag

    hopefully at conference Kim can show real gains that is Monday? so news this weekend is a possibility. if he cancels monday a deal may be in works something to watch for

  • the TImes of India Reports ..

    n a statement issued by WHO South-East Asia Regional Director Dr Poonam Khetrapal Singh, the global health body noted that the virus is of concern in the South-East Asia region as the Aedes aegypti mosquito, responsible for its spread, is found in many areas in the region. Besides, there is no evidence of immunity to the virus among people in these countries.
    In the past, sporadic Zika virus cases have been reported from Thailand and the Maldives.
    The Zika virus, first discovered in Uganda in 1947, is spread through bites from Aedes aegypti mosquito, the vector for dengue. The most common symptoms of Zika virus disease are fever, rash, joint pain, and conjunctivitis. The illness is usually mild with the symptoms lasting a week.
    Dr Khetrapal Singh has urged countries to share information on suspected Zika virus disease to enable early detection and containment of any outbreak in the South-East Asia region.

  • opele1 opele1 Feb 3, 2016 9:16 AM Flag

    this is a hell of alot more serious than ebola

  • opele1 opele1 Feb 3, 2016 9:11 AM Flag

    you keep looking into the past. when the future is where the money is to be made. Value global health emergency in a globalized world make the platform INO developed undervalued. At any time a big company might throw them some $ just to have skin in the game. The CEO is not some piker from suny.

  • A 28-year-old man was infected while traveling in Colombia, a 28-year-old man contracted the virus in Venezuela and a 35-year-old man got the virus in Brazil.

    Chile's Easter Island, some 3,700 km (2,300 miles) from the mainland, does have the mosquito that carries the disease and had 173 Zika cases in 2014. All the Zika cases on Easter Island were "mild" and no pregnant women presented any complications due to the infection, Chilean health authorities said.

    The World Health Organization has said the virus, linked to severe birth defects in Brazil, has been spreading rapidly in the Americas and could infect 4 million people. It said it had launched a global response unit to fight the mosquito-borne virus, which is spreading rapidly in Latin America.

    Africa and Asia are also seen as being vulnerable.

  • opele1 opele1 Feb 3, 2016 9:05 AM Flag

    mers vaccine trial currently enrolling HUMANs

  • Pfizer Inc , Johnson and Johnson and Merck & Co Inc said they were evaluating their technologies or existing vaccines for their potential to combat Zika, a rapidly spreading mosquito-borne disease linked to birth defects

    A number of drug developers and universities are attempting to produce a vaccine for Zika, which the World Health Organization (WHO) has declared an international health emergency.

    Japan's Takeda Pharmaceutical Co Ltd said on Wednesday it had created a team to investigate how it might help make a vaccine, a day after Sanofi SA said it would launch a Zika vaccine program.

    Meanwhile, the first known case of virus transmission in the United States was reported in Texas on Tuesday by local health officials.

    Paul Stoffels, chief scientific officer at Johnson and Johnson's Janssen unit, said the company is currently evaluating if any of its available technologies could be directed to address Zika.

    "At this stage, it is premature to say how long this might take or speculate on the outcome," Stoffels told Reuters in an email.

    Merck, which helped develop the first successful Ebola vaccine, said late on Tuesday it was working with public health partners to see how its expertise could be useful.

    (Reporting by Amrutha Penumudi and Natalie Grover in

    But scientists and experts have said producing a safe and effective vaccine will take time.

    "Pfizer is currently analyzing its existing vaccines portfolio in response to the Zika outbreak to see where we might be able to play a role," Pfizer spokeswoman Sharon Castillo told Reuters in an email.

  • opele1 opele1 Feb 3, 2016 8:47 AM Flag

    if the connection to Microcephaly is verified scientifically you are looking at hundreds of millions of women in north and south america immediately in need of product. Overtime this becomes a mandatory vaccination billions up billions. this could be the most important vaccination of the 21st century.

  • the whole business model of vaccine development needs overhauling to incentivize mid-sized biotech firms and product development partnerships, which he’s involved in, to help find solutions.

    “The model at the moment is too dependent on multinational pharma companies,” he said. “At the moment, big pharma is just sitting on the fence waiting for a big enough incentive for them to make a vaccine.”

  • “Normally you are talking between three to 10 years to get everything properly approved,” he said. “We can use the technologies from other flaviviruses to get the product made by the end of 2016. Testing the efficacy of the drug could take a year or more but if you were in an emergency situation you could do this at the same time as the testing and make it available as soon as it shows efficacy. So you could get something out in 2017, on an accelerated emergency basis.”

    Fauci said the first phase of development will determine whether this accelerated pace will be maintained – any complications will set back the process. But he is confident that pregnant women can be properly protected.

    “It’s complicated because we want to make it safe for pregnant women but we’d start off with non-pregnant women first then, if it were safe, we’d get pregnant volunteers,” he said. “If you are dealing with an inert vaccine, you could do this fairly quickly. But you’d do it very carefully. Ideally you want to protect women before they are pregnant, vaccinate them before child-bearing age.”

  • We are just completely unwilling to take the chance” of having an affected baby, she told the Post.

    After being connected with Hoskins’ office Tuesday, the woman said she and her husband “are overjoyed.

    “We just want this relief. That was the most important thing — to have answers and information to help make the most responsible decisions,” she said.

    The antibody test can produce “false positives” if the person has been infected with such other related viruses as dengue, or has received a yellow fever vaccine, neither of which the Toronto woman says she has been exposed to.

    The World Health Organization has declared Zika virus a “public health emergency” requiring a global response, a designation last issued for Ebola.

  • The Ontario government intervened Tuesday in the case of a pregnant Toronto woman originally denied testing for the Zika virus after her story was reported in the Post.

    Ontario Health Minister Eric Hoskins’ office said it is working with public health staff to arrange antibody testing for the woman, who is 10 weeks pregnant and travelled with her husband to Brazil in December.

    “We’ve got a pregnant woman who is under some stress, and rightfully so, and we just want to make sure she gets the test,” Shea Greenfield, spokesman for Hoskins, told the Post Tuesday.

    Canada’s federal public health agency is expected to soon release updated guidelines for Zika virus testing of Canadians who may have been exposed to the mosquite-transmitted infection while travelling in affected regions.

    The Toronto couple spent 12 days in Brazil in late December. The woman, who spoke on condition of anonymity because she and her husband have not yet told their families they are expecting, said she was told this week she did not qualify for blood testing for the mosquito-transmitted infection — which is suspected, thought not scientifically proven, of causing microcephaly, or abnormally small heads and brain damage in newborns — because she was “asymptomatic,” meaning she hasn’t exhibited signs of infection.

  • head of special pathogens at the Public Health Agency of Canada.

    Kobinger, known for his work in the treatment of the Ebola virus, has collaborated with researchers at Inovio for several years. He met them during his years in post-doctoral studies at the University of Pennsylvania.

  • LAURENT HUMEAU is the Vice President of Research & Development, based at the Inovio San Diego Research Center. Laurent provides the technical and strategic leadership for the R&D group including: preclinical development of immunotherapy and vaccine candidates, immunology and immune monitoring approaches, method development, product characterization, and analytical development. Prior to Inovio, Laurent was Senior Director of Translational Research, Human Therapeutics Division for Intrexon and previously Chief Scientific Officer, Vice President of R&D at VIRxSYS Corporation. Laurent holds a Ph.D., summa cum laude, from Denis Diderot/Paris 7 university and a MS degree from Pierre & Marie Curie/Paris 6 university, Paris, France.

  • SCOTT M. WHITE joined Inovio Pharmaceuticals as Vice President, Clinical Development in February 2015 where he has responsibility for the clinical development of the infectious diseases portfolio. Prior to joining Inovio he was a Senior Director with GlaxoSmithKline where he had led the worldwide clinical development of several products spanning antibacterial, antiviral, hematologic and dermatologic therapeutic areas. In 2012 he was the industry project leader for the design and establishment of the COMBACTE EU Clinical Trial Network for antibacterial agents funded through the Innovative Medicines Initiative public private partnership program. Dr. White was an assistant professor of medicine at the University Of Pittsburgh School Of Medicine and the Baylor College of Medicine where he led NIH-funded research into the role of hematopoietic growth factors in normal and pathologic blood cell development and function.

  • The American Red Cross requested Tuesday that prospective blood donors who have traveled to places affected by the Zika virus wait at least 28 days before donating their blood, Reuters reported. The “self-deferral” should apply to people who visited Mexico, the Caribbean and Central or South America during the past four weeks.

    Earlier this week, the World Health Organization deemed the Zika virus outbreak a public health emergency of international concern, citing an unproved but strongly suspected link between the virus and a birth defect known as microcephaly. The mosquito-borne virus has affected more than 30 countries and territories. Earlier Tuesday, the first known case of Zika virus transmission in the United States was reported in Texas. Local health officials said the illness was likely contracted through sex and not a mosquito bite.

IRBT
33.70-0.71(-2.06%)Feb 5 4:00 PMEST